Improving surgical decisions for young women with breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to enhance the surgical decision-making process for young women diagnosed with breast cancer by utilizing a web-based tool called CONSYDER. Participants will complete surveys before and after their surgical consultations to assess the tool's effectiveness in reducing decisional conflict and improving communication with surgeons. The study will involve approximately 800 women across four major cancer centers over a 30-month period, employing a multi-site cluster randomized design. The primary focus is to evaluate how CONSYDER impacts decision-making preferences, knowledge, anxiety, and self-efficacy in communication.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female aged 18-44
* New diagnosis of Stage 0, 1, 2, or 3 unilateral breast cancer
* English or Spanish speaking

Exclusion Criteria:

* Diagnosis of de novo Stage 4 breast cancer
* Recurrent early-stage breast cancer
* Bilateral breast cancer

Where it's running

• Yale Cancer Center
  New Haven, Connecticut, United States Recruiting
• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting
• Weill Cornell Medicine
  New York, New York, United States Recruiting
• Duke Cancer Institute
  Durham, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Shoshana Rosenberg, ScD, MPH — Weill Medical College of Cornell University
• Study coordinator: Shoshana Rosenberg, ScD, MPH
• Email: shr4009@med.cornell.edu
• Phone: 646-962-8041

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Virtual rehabilitation program for cancer survivors

  This study is testing an 8-week online rehab program for cancer survivors to see if it helps them feel better physically and socially after treatment.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT05898789

• Capecitabine for MRD-positive, resected ER+/HER2-negative breast cancer

  This Phase 2 trial tests whether taking capecitabine can help people with resected, ER-positive/HER2-negative breast cancer who still have molecular residual disease after standard therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT07631052

• Predicting how hormone therapy before surgery affects breast cancer

  This study is testing how hormone therapy before surgery can help people with early-stage breast cancer and what it means for their tumors.

  Recruiting Phase 2 George Washington University · Washington D.C., District of Columbia · NCT06806930

• Meal timing during cancer treatment for Alaska Native and American Indian patients

  This test will see if an 8-hour time-restricted eating schedule during neoadjuvant or adjuvant therapy helps Alaska Native and American Indian adults with rectal or certain breast cancers.

  Recruiting Fred Hutchinson Cancer Center · Anchorage, Alaska · NCT06802172

• Memantine plus structured exercise to protect thinking and memory during breast cancer chemotherapy

  This will test whether memantine combined with a supervised exercise program, memantine alone, or a placebo can prevent or reduce thinking and memory problems in people receiving chemotherapy for stage I–III breast cancer.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06727773

• Using tart cherry juice to prevent nerve damage from chemotherapy in breast cancer patients

  This study is testing if drinking tart cherry juice can help prevent nerve damage in breast cancer patients receiving chemotherapy.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06268665

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.